[1] |
LI Dong, SONG Yana, WANG Ligang, BIAN Rongrong, ZHAO Yan.
Considerations for Establishing National Sentinel Hospitals for Medical Device Adverse Event Monitoring
[J]. Chinese Journal of Pharmacovigilance, 2025, 22(7): 780-785.
|
[2] |
LIANG Fanglin, CHEN Lingyuan, HU Danli, WEI Lingyun, WEI Tiemeng, ZHANG Faen, WEI Yana.
Immune-Related Adverse Events of Tislelizumab in 120 Patients with Hepatocellular Carcinoma
[J]. Chinese Journal of Pharmacovigilance, 2025, 22(6): 659-663.
|
[3] |
ZOU Yuanlei, XIA Qingrong, LIANG Jun, HE Kongliang, MO Daming, WU Wenning.
Words of Warning and Preventive Measures in Labels of Antidepressants
[J]. Chinese Journal of Pharmacovigilance, 2025, 22(3): 329-333.
|
[4] |
XIA Lanfang, LI Keli, WANG Lei, LI Yan, WANG Huaqing.
Impact of comparator selection on signal detection in adverse events following immunization in China
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(7): 798-804.
|
[5] |
ZHANG Jian, ZHANG Lingli, LI Xin.
Immune-related adverse events of tirelizumab in 424 cases of cancer patients
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(4): 435-439.
|
[6] |
ZHANG Bing, SA Rina, ZHANG Xiaomeng, ZHANG Dan, LIN Zhijian, WANG Yu.
Research progress in pharmacogenic cardiotoxicity
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(8): 841-847.
|
[7] |
ZHAO Huanhuan, SONG Jiawei, LIU Jinguang, HUANG Minghui.
One case of nephrotic syndrome caused by rabies vaccine in a 5-year-old child
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(11): 1303-1305.
|
[8] |
WANG Tao, ZHENG Mingjie, LIU Hongliang, WANG Qing, SHEN Chuanyong.
Current applications of artificial intelligence in pharmacovigilance in the USA and implications
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(10): 1129-1133.
|
[9] |
YU Min, LI Xin.
Immunerelated adverse events and risk factors of carrelizumab in 528 cases of cancer patients
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(10): 1134-1140.
|
[10] |
CHEN Shuang, ZHENG Shufen, ZHANG Shuyao, ZHONG Shilong.
Adverse reactions of tumor immunotherapy drugs—PD-1/PD-L1 inhibitors
[J]. Chinese Journal of Pharmacovigilance, 2022, 19(10): 1107-1112.
|
[11] |
Chen Aihong, Yin Qiangbing, Li Huadan, Wu Nengjian.
Analysis of Monitoring Reports on Suspected Adverse Events Following Immunization in Pingshan District Shenzhen City during 2015~2018
[J]. Chinese Journal of Pharmacovigilance, 2021, 18(5): 464-468.
|
[12] |
LI Xinxu, TANG Zhimin, ZHOU Jun, WANG Jun.
Limitations of the Safety Assessment in Premarketing Clinical Trials of Drugs and Suggestions for Improvement
[J]. Chinese Journal of Pharmacovigilance, 2020, 17(8): 465-470.
|
[13] |
JIANG RuiJu, YIN QiongZhou, XU MingJue, ZHAO ZhiMei, DENG Yan, NING Ruotong, CHE YanChun.
Adverse Events Induced by Immunization of Concomitant Inoculation of Freeze-dried Hepatitis A (Live) Vaccine with Vaccines for National Immunization Program from Surveillance Data
[J]. Chinese Journal of Pharmacovigilance, 2020, 17(10): 710-714.
|
[14] |
LI Xiaodan, ZHANG Yangxin, LIU Chen, BAI Xiangrong, YAN Suying.
Retrospective Analysis of Adverse Reactions and Prognosis of Six Contrast Agents from 2011 to 2018
[J]. Chinese Journal of Pharmacovigilance, 2019, 16(7): 436-441.
|
[15] |
SUN Yixin, MENG Kangkang, XIA Yukun, XIONG Weiyi, DENG Siwei, DONG Duo, ZHAN Siyan.
Incidence of Cardiac Adverse Events of Cisapride: a Systematic Review and Meta-analysis
[J]. Chinese Journal of Pharmacovigilance, 2019, 16(2): 94-100.
|